NCT04629976 - Activity of NCO-48 Fumarate in Treatment-Naive Adults With Chronic Hepatitis B | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 12, 2021

Primary Completion Date

September 30, 2022

Study Completion Date

December 28, 2022

Conditions

Chronic Hepatitis B

Interventions

DRUG

NCO-48 Fumarate 4 mg

2 x 2mg NCO-48 Fumarate over 28 days of therapy

DRUG

NCO-48 Fumarate 20 mg

2 x 10 mg NCO-48 Fumarate over 28 days of therapy

DRUG

Tenofovir Alafenamide 25 mg

25 mg over 28 days of therapy

Trial Locations (1)

National Institute of Clinical Research, Inc, Monterey Park